Clinical Report: Access to High-Expense Cancer Treatments for Children in Canada
Overview
This study identifies significant disparities in access to high-cost cancer therapies for children in Canada, highlighting barriers such as travel and funding issues. Recommendations for policy changes include universal funding and the establishment of specialized treatment centers.
Background
Access to innovative cancer therapies for children in Canada is often inequitable due to the high costs and lack of public funding for certain treatments. This situation necessitates a better understanding of the barriers faced by pediatric oncology providers and their patients. Addressing these disparities is crucial for improving treatment outcomes and ensuring that all children have access to effective therapies.
Data Highlights
Therapy
Access Rate (%)
Respondents (n)
Blinatumomab
89
35
Larotrectinib
79
27
Proton Beam Therapy
59.2
30
Tisagenlecleucel
94
30
Key Findings
Access rates for blinatumomab, larotrectinib, PBT, and tisagenlecleucel were reported at 89%, 79%, 59.2%, and 94%, respectively.
Key barriers included patient/family inability to travel and the economic impact of travel.
The high cost of larotrectinib was identified as a significant barrier to access.
Most respondents were pediatric medical oncologists, indicating a specialized focus in the survey.
Universal funding and simplified approval processes are recommended to improve access.
Clinical Implications
Healthcare providers should be aware of the disparities in access to high-cost cancer therapies and advocate for policy changes that promote equitable access. Understanding the barriers faced by families can help in developing supportive measures to facilitate treatment access.
Conclusion
The findings underscore the need for systemic changes in Canada to ensure equitable access to high-cost cancer therapies for children. Addressing these barriers is essential for improving treatment outcomes in pediatric oncology.
Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development
Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)
Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.
